Sunday, June 4, 2006
OncoLink coverage of the Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, in Atlanta, GA OncoLink reporters provide in-depth, up-to-the-minute coverage of sessions and presentations.
A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) Induction cisplatin (P) and fluorouracil (F) with or without docetaxel (T) followed by chemoradiation (CTRT) and surgical resection as indicated for locally advanced squamous cell carcinoma (LASCC) of the head & neck: preliminary results from the TAX 324 Intergroup RTOG 98-11: A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alpha (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Phase III trial of intermittent MAB vs continuous MAB Postoperative concurrent radiochemotherapy (RCT) versus radiotherapy (RT) in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96-3 Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01 RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP or autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma (MM) The impact of FLIPI on outcome of frontline treatment with single-agent I-131 tositumomab for follicular lymphoma (FL) The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation.